| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | V116 - (STRIDE-6) | Pneumococcal Conjugate Vaccine | Phase 3 | Data Released | Intramuscular | Immunology |
| Ligand Pharmaceuticals Incorporated | VK2809 - (VOYAGE) | Non-alcoholic steatohepatitis (NASH) and fibrosis | Phase 2b | Data Released | oral | Gastroenterology |
| Ligand Pharmaceuticals Incorporated | AT278-AID System | Diabetes | Phase 2 | Trial Planned | Transdermal | Endocrinology |
| Ligand Pharmaceuticals Incorporated | Ganaxolone | Fragile X Syndrome | Phase 2 | Trial Discontinued | Oral Intravenous | Genetic Disorder |
| Ligand Pharmaceuticals Incorporated | Ganaxolone - (Magnolia) | Postpartum depression | Phase 2 | Trial Discontinued | Oral | Psychiatric |
| Ligand Pharmaceuticals Incorporated | Ensifentrine (RPL554) - Metered Dose Inhaler | Chronic obstructive pulmonary disease (COPD) | Phase 2 | Trial Completed | Inhalation | Respiratory |
| Ligand Pharmaceuticals Incorporated | Ensifentrine (RPL554) DPI formulation | Maintenance treatment of COPD | Phase 2 | Trial Discontinued | Inhalation | Respiratory |
| Ligand Pharmaceuticals Incorporated | Lasofoxifene + Abemaciclib - (ELAINE 2) | ER+/HER2- Breast Cancer | Phase 2 | Data Released | Oral | Oncology |